A phase III trial of muparfostat (PI-88) as adjuvant therapy in patients with hepatitis virus related hepatocellular carcinoma (HV-HCC) after resection | |
Chen, P-J.; Lee, P-H.; Han, K-H.; Fan, J.; Cheung, T. T.; Hu, R-H.; Paik, S. W.; Lee, W-C.; Chau, G-Y.; Jeng, L-B. | |
2017 | |
卷号 | 28 |
ISSN号 | 0923-7534 |
URL标识 | 查看原文 |
收录类别 | SCIE |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/6363683 |
专题 | 中国医学科学院 北京协和医学院 |
推荐引用方式 GB/T 7714 | Chen, P-J.,Lee, P-H.,Han, K-H.,et al. A phase III trial of muparfostat (PI-88) as adjuvant therapy in patients with hepatitis virus related hepatocellular carcinoma (HV-HCC) after resection[J],2017,28. |
APA | Chen, P-J..,Lee, P-H..,Han, K-H..,Fan, J..,Cheung, T. T..,...&Lai, K-L..(2017).A phase III trial of muparfostat (PI-88) as adjuvant therapy in patients with hepatitis virus related hepatocellular carcinoma (HV-HCC) after resection.,28. |
MLA | Chen, P-J.,et al."A phase III trial of muparfostat (PI-88) as adjuvant therapy in patients with hepatitis virus related hepatocellular carcinoma (HV-HCC) after resection".28(2017). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论